FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921692877> ?p ?o ?g. }

• W2921692877 endingPage "37" @default.
• W2921692877 startingPage "29" @default.
• W2921692877 abstract "Renal fibrosis is the most common final stage of progressive renal disease, characterized by fibroblast proliferation, fibroblast-to-myofibroblast differentiation and excessive accumulation of extracellular matrix. Dihydroartemisinin (DHA) exerts antitumor, antibacterial, and antifibrotic effects. The aim of this study was to determine whether DHA has beneficial effects on unilateral ureteral obstruction (UUO)-induced renal fibrosis in mice and to examine explore the underlying possible mechanisms. Eight-week-old male C57BL/6 mice were intragastrically administered DHA for 14 consecutive days after UUO operation. Afterward, interstitial collagen deposition, expression of collagen I and III, fibronectin, α-smooth muscle actin (α-SMA), proliferating cell nuclear antigen (PCNA), and S100 calcium-binding protein A4 (S100A4) were assessed in the kidneys. Transforming growth factor beta 1 (TGF-β1)-induced primary human kidney fibroblasts were treated with DHA to further investigate the mechanism underlying its action. In vivo, DHA reduced UUO-induced morphological and pathological changes and the degree of renal fibrosis. In addition, DHA mitigated fibroblast proliferation and differentiation in kidney tissue induced by UUO. In vitro, DHA significantly attenuated the TGF-β1-induced primary human kidney fibroblast proliferation and fibroblast-to-myofibroblast differentiation. Moreover, treatment with DHA attenuated the up-regulation of phosphorylation of phosphatidylinositol-3-kinase (PI3K) and protein kinase B (AKT) in UUO model and TGF-β1-induced primary human kidney fibroblasts. We provide in vivo and in vitro evidence that DHA may relieve renal fibrosis through regulation of fibroblast proliferation and differentiation by mitigating the PI3K/AKT pathway. DHA may potentially be used as a therapeutic antifibrotic agent for the treatment of renal fibrosis." @default.
• W2921692877 created "2019-03-22" @default.
• W2921692877 creator A5011877804 @default.
• W2921692877 creator A5021983976 @default.
• W2921692877 creator A5030885222 @default.
• W2921692877 creator A5037264874 @default.
• W2921692877 creator A5039879976 @default.
• W2921692877 creator A5040582111 @default.
• W2921692877 creator A5062047914 @default.
• W2921692877 creator A5064684366 @default.
• W2921692877 creator A5076001689 @default.
• W2921692877 creator A5080134626 @default.
• W2921692877 creator A5087018671 @default.
• W2921692877 date "2019-04-01" @default.
• W2921692877 modified "2023-10-15" @default.
• W2921692877 title "Dihydroartemisinin attenuates renal fibrosis through regulation of fibroblast proliferation and differentiation" @default.
• W2921692877 cites W1971970237 @default.
• W2921692877 cites W1998329843 @default.
• W2921692877 cites W2026556401 @default.
• W2921692877 cites W2027693573 @default.
• W2921692877 cites W2035391762 @default.
• W2921692877 cites W2051174713 @default.
• W2921692877 cites W2052092179 @default.
• W2921692877 cites W2069374568 @default.
• W2921692877 cites W2078657995 @default.
• W2921692877 cites W2101766543 @default.
• W2921692877 cites W2102777569 @default.
• W2921692877 cites W2106408170 @default.
• W2921692877 cites W2166272576 @default.
• W2921692877 cites W2320783464 @default.
• W2921692877 cites W2331129278 @default.
• W2921692877 cites W2342679639 @default.
• W2921692877 cites W2545247739 @default.
• W2921692877 cites W2562674945 @default.
• W2921692877 cites W2737832093 @default.
• W2921692877 cites W2772641177 @default.
• W2921692877 cites W2781123234 @default.
• W2921692877 cites W2802394927 @default.
• W2921692877 cites W2804045132 @default.
• W2921692877 cites W2884427722 @default.
• W2921692877 cites W2891534760 @default.
• W2921692877 cites W2891629413 @default.
• W2921692877 doi "https://doi.org/10.1016/j.lfs.2019.03.020" @default.
• W2921692877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30862567" @default.
• W2921692877 hasPublicationYear "2019" @default.
• W2921692877 type Work @default.
• W2921692877 sameAs 2921692877 @default.
• W2921692877 citedByCount "30" @default.
• W2921692877 countsByYear W29216928772019 @default.
• W2921692877 countsByYear W29216928772020 @default.
• W2921692877 countsByYear W29216928772021 @default.
• W2921692877 countsByYear W29216928772022 @default.
• W2921692877 countsByYear W29216928772023 @default.
• W2921692877 crossrefType "journal-article" @default.
• W2921692877 hasAuthorship W2921692877A5011877804 @default.
• W2921692877 hasAuthorship W2921692877A5021983976 @default.
• W2921692877 hasAuthorship W2921692877A5030885222 @default.
• W2921692877 hasAuthorship W2921692877A5037264874 @default.
• W2921692877 hasAuthorship W2921692877A5039879976 @default.
• W2921692877 hasAuthorship W2921692877A5040582111 @default.
• W2921692877 hasAuthorship W2921692877A5062047914 @default.
• W2921692877 hasAuthorship W2921692877A5064684366 @default.
• W2921692877 hasAuthorship W2921692877A5076001689 @default.
• W2921692877 hasAuthorship W2921692877A5080134626 @default.
• W2921692877 hasAuthorship W2921692877A5087018671 @default.
• W2921692877 hasConcept C126322002 @default.
• W2921692877 hasConcept C134018914 @default.
• W2921692877 hasConcept C185592680 @default.
• W2921692877 hasConcept C189165786 @default.
• W2921692877 hasConcept C202751555 @default.
• W2921692877 hasConcept C207865475 @default.
• W2921692877 hasConcept C2780381497 @default.
• W2921692877 hasConcept C2780559512 @default.
• W2921692877 hasConcept C502942594 @default.
• W2921692877 hasConcept C55493867 @default.
• W2921692877 hasConcept C62478195 @default.
• W2921692877 hasConcept C71924100 @default.
• W2921692877 hasConcept C75217442 @default.
• W2921692877 hasConcept C86492073 @default.
• W2921692877 hasConcept C86554907 @default.
• W2921692877 hasConcept C86803240 @default.
• W2921692877 hasConcept C95444343 @default.
• W2921692877 hasConceptScore W2921692877C126322002 @default.
• W2921692877 hasConceptScore W2921692877C134018914 @default.
• W2921692877 hasConceptScore W2921692877C185592680 @default.
• W2921692877 hasConceptScore W2921692877C189165786 @default.
• W2921692877 hasConceptScore W2921692877C202751555 @default.
• W2921692877 hasConceptScore W2921692877C207865475 @default.
• W2921692877 hasConceptScore W2921692877C2780381497 @default.
• W2921692877 hasConceptScore W2921692877C2780559512 @default.
• W2921692877 hasConceptScore W2921692877C502942594 @default.
• W2921692877 hasConceptScore W2921692877C55493867 @default.
• W2921692877 hasConceptScore W2921692877C62478195 @default.
• W2921692877 hasConceptScore W2921692877C71924100 @default.
• W2921692877 hasConceptScore W2921692877C75217442 @default.
• W2921692877 hasConceptScore W2921692877C86492073 @default.
• W2921692877 hasConceptScore W2921692877C86554907 @default.
• W2921692877 hasConceptScore W2921692877C86803240 @default.

• next